Chronic Lymphocytic Leukemia | Clinical

Details of Different Therapies and Modalities Decide Treatment of CLL in the Second Line

January 13, 2021

For the second-line treatment of patients with chronic lymphocytic leukemia, the armamentarium includes many therapies and strategies. Danielle Brander, MD, assistant professor of Medicine at Duke Cancer Institute, discussed how to select treatment for patients during a Targeted Oncology Case-Based Peer Perspectives event.

Ibrutinib-Based 1L Therapy Sustains Efficacy, Safety in TP53+ Chronic Lymphocytic Leukemia

January 12, 2021

The sustainability of efficacy and safety with frontline ibrutinib-based therapy used to treat patients with chronic lymphocytic leukemia who have TP53 aberrations was demonstrated, according to 4-year follow-up result of a pooled analysis.

Venetoclax Makes Inroads Into More Hematologic Setting

December 30, 2020

Expanding beyond the chronic lymphocytic leukemia/ small lymphocytic lymphoma space, the BCL2 inhibitor venetoclax garnered attention in 2020 for positive reports from phase 3 clinical trials exploring its use in acute myeloid leukemia and multiple myeloma.

Benefit From MURANO Trial in CLL Sustained With Subsequent Therapy

December 09, 2020

An analysis from the MURANO trial showed that venetoclax in combination with rituximab led to a more than doubling of time to next treatment compared with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia.

Acalabrutinib Demonstrates Low Cardiac Risk in Chronic Lymphocytic Leukemia

December 08, 2020

In a pooled analysis of 4 clinical trials in chronic lymphocytic leukemia, patients who received treated with acalabrutinib monotherapy had a low incidence of cardiac toxicities leading to treatment discontinuation, according to a presentation given during the American Society of Hematology Annual Meeting.

Significant Responses Seen With Investigational BTK Inhibitor in Pretreated CLL/SLL Population

December 08, 2020

A high objective response rate was observed in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma treated with LOXO-305, according to results of the phase 1/2 BRUIN trial presented during the 2020 ASH Annual Meeting.